JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (1): 29-32.doi: 10.6040/j.issn.1671-7554.0.2015.413

Previous Articles     Next Articles

Risk factors to influence renal function of patients with chronic hepatitis B virus infection

QIAN Yu, QU Yundong, WANG Ziyu, LIU Feng, YE Qian, WANG Lei   

  1. Department of Hepatology, The Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2015-04-24 Online:2016-01-11 Published:2016-01-11

Abstract: Objective To assess the renal function of patients with chronic hepatitis B virus(HBV)infection and to explore the risk factors for renal dysfunction. Methods A total of 206 treatment-naïve patients with chronic HBV infection were enrolled, including 151 cases of chronic hepatitis B(CHB)and 55 cases of liver cirrhosis. The renal function with estimated glomerular filtration rate(eGFR)was calculated with latest Chronic Kidney Disease Epidemiology Collaboration(CKD-EPI)equation. The prevalence of renal impairment [eGFR < 90 mL/(min·1.73 m2)] was evaluated and risk factors for renal abnormalities were analyzed. Results The total incidence of renal impairment was 21.85%(45/206), while it was 17.88%(27/151)and 32.73%(18/55)among CHB patients and liver cirrhosis patients, with the latter being significantly higher than the former(χ2= 5.205, P=0.023). Age(≥50 years)and history of hypertension were identified as risk factors for renal impairment. Conclusions Renal abnormalities pre-exist in some patients with chronic HBV infection before the initiation of any antiviral treatment. Age and history of hypertension are identified as risk factors for renal impairment. We need to evaluate renal function in patients with chronic HBV infection at baseline and monitor renal function regularly.

Key words: Glomerular filtration rate, Renal function impairment, Chronic hepatitis B

CLC Number: 

  • R512.6+2
[1] Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane[J]. Lancet, 1971, 2(7718): 234-237.
[2] Zeng CH, Chen HM, Wang RS, et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients[J]. Am J Kidney Dis, 2008, 52(4): 691-698.
[3] Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil[J]. Hepatology, 2009, 50(3): 727-734.
[4] Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C[J]. N Engl J Med, 2012, 367(1): 20-29.
[5] Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD[J]. Am J Kidney Dis, 2014, 63(5): 713-735.
[6] Thyagarajan SP, Thirunalasundari T, Subramanian S, et al. Serum and tissue positivity for hepatitis B virus markers in histopathologically proven glomerulonephropathies[J]. J Med Microbiol, 1989, 29(4): 243-249.
[7] Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Ann Intern Med, 2003, 139(2): 137-147.
[8] 钟爱民, 刘燕鸣, 陈红, 等. 血清胱抑素-C是反映肾小球滤过功能的敏感指标[J]. 临床肾脏病杂志, 2004, 4(4): 166-167. ZHONG Aimin, LIU Yanming, CHEN Hong, et al. Serum cystatin C is a sensitive and accurate marker of glomerular filtration rate[J]. J Clin Nephrol, 2004, 4(4):166-167.
[9] Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes[J]. JAMA, 2010, 303(5): 423-429.
[10] 刘红春, 苏利沙, 赵占正, 等. 血清胱抑素C评估慢性肾脏病患者肾小球滤过率的应用研究[J]. 中华检验医学杂志, 2014, 37(3): 184-188. LIU Hongchun, SU Lisha, ZHAO Zhanzheng, et al. The evaluation of glomerular filtration rate in chronic kidney disease patients based on serum CysC[J]. Chin J Lab Med, 2014, 37(3): 184-188.
[11] Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B[J]. Hepatol, 2011, 55: 1235-1240.
[12] Amet S, Bronowicki JP, Thabut D, et al. Prevalence of renal abnormalities in chronic HBV infection: The HARPE study[J]. Liver Int, 2015, 35(1): 148-155.
[13] Kim YJ, Cho HC, Sinn DH, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J]. J Gastroenterol Hepatol, 2012, 27(2): 306-312.
[14] Tan LK, Gilleece Y, Mandalia S, et al. Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir[J]. J Viral Hepat, 2009, 16(7): 471-478.
[15] 张斌, 万谟彬. 肝肾综合征发病机理[J]. 世界感染杂志, 2002, 2(5-6): 385-387. ZHANG Bin, WAN Mobin. The pathogenesis of hepatorenal syndrome[J]. Infection Journal of the World, 2002, 2(5-6): 385-387.
[16] 刘颖, 樊荣, 陈简, 等. 慢性乙型肝炎病毒感染相关肝硬化患者的肾功能及危险因素分析[J]. 南方医科大学学报, 2014, 34(4): 472-476. LIU Ying, FAN Rong, CHEN Jian, et al. Assessment of renal function and risk factors for renal impairment in patients with hepatitis B virus-related liver cirrhosis[J]. J South Med Univ, 2014, 34(4): 472-476.
[17] Chen N, Wang W, Huang Y, et al. Community-based study on CKD subjects and the associated risk factors[J]. Nephrol Dial Transplant, 2009, 24(7): 2117-2123.
[18] Tanaka M, Suzuki F, Seko Y, et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B[J]. J Gastroenterol, 2014, 49(3): 470-480.
[1] LIU Qiuxia, WANG Lei, LIU Feng, QU Yundong, YE Qian, QIAN Yu, ZHANG Yuan, ZHANG Lixin. Hypophosphatemia during long-term adefovir dipivoxil therapy in patients with hepatitis B virus infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 73-78.
[2] ZHANG Kun, ZHAGN Xiaoguo, CUI Xingxing, CHEN Shijun. Expression of apoptosis-related genes in peripheral blood mononuclear cells of patients with HBV infection and the relationship with chronicity of hepatitis B [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 38-42.
[3] LIU Tongyan1, ZHANG Longyue2, LI Yuerong3, SUN Jingli2, HAN Zenglu3, LI Zhiquan1, ZHANG Lixin1, WANG Lei1. Prospective cohort observation of patients with hepatitis B e antigen-positive chronic hepatitis B treated by Adefovir dipivoxil and Interferon-α [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 72-78.
[4] PAN Jiachao1,2, ZHANG Le1,2, XU Linlin3, SHAN Xiaoyu2, DU Wenjun2, CHEN Shijun2. Role of innate immunity induced by AIM2 in the pathogenesis of chronic hepatitis B [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 74-79.
[5] LIU Wei1, DING Ai-kun2, LI Cheng2, SHAN Rong3, WANG Chang-yuan1,2. Significance and influential factors of Fibroscan detection  in the progress of patients with chronic hepatitis B disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 85-88.
[6] FU Xiao-li, WANG Lei, LIU Feng. HBsAg quantitative value in different stages of hepatitis B virus infection and its correlations with serum HBV DNA and age [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(5): 94-98.
[7] ZHANG Xiu-zhen, LIU Li, LIU Qian. Relativity of serum leptin level and response to antiviral
therapy in patients with chronic hepatitis B
[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 96-99.
[8] MA Min1, ZHANG Liang2, SHAO Guang-feng1, ZHANG Lei1, LIU Yu-qiang1. Relationship between collagen type Ⅲ in serum and
renal function in  obstructive  nephropathy
[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 62-65.
[9] LI Xiao-ying,WANG Lei,LIU Feng. Durability of the effects after cessation of lamivudine for 47 patients with HBeAg-negative chronic hepatitis B [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(9): 938-939.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!